Fig. 3: Longitudinal ctDNA analysis for relapse anticipation and disease monitoring.
From: Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
a The dynamic monitoring of ctDNA in patients with radiological recurrence. Circles represented ctDNA status. Treatment and imaging information was indicated for each patient. Patients were separated based on their pretreatment ctDNA shedding status. b The comparison of the recurrence time measured by ctDNA versus computed tomography (CT). Two-sided Wilcoxon two-sample paired signed-rank test, p < 0.001. c CT scan and ctDNA detection for patient P017. d CT scan and ctDNA detection for patient P072.
